Product Description
Piperacillin is one of the new generation of semisynthetic penicillins which can be administered intravenously or intramuscularly. It has a broad spectrum of activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/6391888/)
Mechanisms of Action: LACTB Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Acute Respiratory Distress Syndrome|COVID-19|Enterobacteriaceae Infections|Influenza, Human|Pneumonia|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated
Phase 2: Pyelonephritis|Urinary Tract Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| REMAP-CAP | P3 |
Recruiting |
COVID-19|Influenza, Human|Pneumonia |
2026-02-01 |
|
| 2022-002636-31 | P3 |
Active, not recruiting |
Enterobacteriaceae Infections |
2025-12-09 |
|
| FRENCH24 ANIS | P3 |
Active, not recruiting |
Unknown |
2025-04-03 |
|
| ASPIC | P3 |
Active, not recruiting |
Pneumonia|Acute Respiratory Distress Syndrome |
2021-07-27 |